Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1123-1124. Epub 2016 Aug 2.

Authors

Francesco Carubbi¹, Paola Cipriani², Paola Di Benedetto², Piero Ruscitti², Alessia Alunno³, Roberto Gerli³, Roberto Giacomelli²

Affiliations

¹ Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy; and Department of Medicine, ASL 1 Avezzano-Sulmona-L'Aquila, Italy. francescocarubbi@libero.it.
² Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, Italy.
³ Department of Medicine, Rheumatology Unit, University of Perugia, Italy.

PMID: 27494407

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD / metabolism
Antirheumatic Agents / therapeutic use*
B-Cell Activating Factor / metabolism*
Humans
Rituximab / therapeutic use*
Salivary Glands / metabolism*
Sialadenitis / complications
Sialadenitis / drug therapy
Sialadenitis / metabolism*
Sjogren's Syndrome / complications
Sjogren's Syndrome / drug therapy
Sjogren's Syndrome / metabolism*

Substances

Antigens, CD
Antirheumatic Agents
B-Cell Activating Factor
TNFSF13B protein, human
Rituximab